UBS Group
CNTB

UBS Group’s Connect Biopharma Holdings CNTB Stock Holding History

UBS Group’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86 Sell
33
-3,132
-99% -$8.16K ﹤0.01% 10139
2025
Q4 		$8.93K Buy
3,165
+2,964
+1,475% +$6.32K ﹤0.01% 8320
2025
Q3 		$304 Buy
201
+159
+379% +$281 ﹤0.01% 9749
2025
Q2 		$41 Sell
42
-8,697
-100% -$6.93K ﹤0.01% 10067
2025
Q1 		$4.81K Buy
8,739
+4,006
+85% +$3.71K ﹤0.01% 9062
2024
Q4 		$6.53K Buy
+4,733
New +$5.45K ﹤0.01% 8554
2023
Q2 		– Sell
-9,336
Closed -$9.34K – 9004
2023
Q1 		$9.34K Sell
9,336
-8,798
-49% -$9.6K ﹤0.01% 7664
2022
Q4 		$15.8K Buy
18,134
+17,638
+3,556% +$14.5K ﹤0.01% 7949
2022
Q3 		$1K Sell
496
-104,689
-100% -$126K ﹤0.01% 9937
2022
Q2 		$91K Buy
105,185
+103,324
+5,552% +$152K ﹤0.01% 5500
2022
Q1 		$6K Buy
1,861
+1,080
+138% +$4.56K ﹤0.01% 8957
2021
Q4 		$4K Buy
781
+346
+80% +$3.85K ﹤0.01% 9504
2021
Q3 		$11K Buy
+435
New +$9.84K ﹤0.01% 7868

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

UBS Group's CNTB Position: Q1 2026 in Review

UBS Group reduced its Connect Biopharma Holdings (CNTB) stake by 99% in Q1 2026, selling an estimated $8.16K and leaving 33 shares worth $86. The position accounts for ﹤0.01% of the portfolio, ranked #10139.

UBS Group first reported a position in CNTB in Q3 2021 and has held it in 13 quarters since. The position peaked at $91K in Q2 2022. 41 funds tracked by Wall St. Rank hold CNTB as of Q1 2026.

  • UBS Group held 33 shares of Connect Biopharma Holdings worth $86 as of Q1 2026.
  • UBS Group sold 3,132 Connect Biopharma Holdings shares in Q1 2026, an estimated $8.16K.
  • Connect Biopharma Holdings made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #10139 holding.
  • UBS Group first reported a position in Connect Biopharma Holdings in Q3 2021 and has held it in 13 quarters since.
  • UBS Group's Connect Biopharma Holdings position peaked at $91K in Q2 2022.
  • 41 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.